• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血清英夫利昔单抗清除率水平值可维持儿科炎症性肠病患者血液学缓解。

Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease.

机构信息

Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Department of Pediatrics, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.

出版信息

Gut Liver. 2019 Sep 15;13(5):541-548. doi: 10.5009/gnl18129.

DOI:10.5009/gnl18129
PMID:30970435
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6743797/
Abstract

BACKGROUND/AIMS: Infliximab (IFX) often loses its therapeutic effect in initial responders with inflammatory bowel disease (IBD) over time. Low serum IFX trough levels (TLs) are linked to poor clinical response and outcomes. Maintenance of optimal therapeutic IFX concentrations is important for sustaining response and achieving good clinical outcomes. Measurement of serum IFX TLs is helpful for determining a further proper therapeutic plan. However, adequate therapeutic IFX TLs in pediatric IBD is uncertain. We aimed to identify the cutoff values for IFX TLs associated with laboratory response to IFX maintenance therapy.

METHODS

Patients with pediatric IBD who had received IFX infusions between December 2008 and March 2015 at Samsung Medical Center were retrospectively investigated. We analyzed 239 blood samples that were collected from 103 pediatric patients. We measured IFX TLs at induction (6 and 14 weeks) and during maintenance therapy (>22 weeks, 8 weeks interval) by fluid-phase radioimmunoassays.

RESULTS

A significant association was found between the erythrocyte sedimentation rate (ESR) and IFX TLs during maintenance (correlation coefficient, -0.11; p=0.0005). A cutoff value of 18 mm/hr for ESR was used to define higher levels. Receiver operating characteristic analysis identified optimal cutoff values: IFX TL >1.58 µg/mL (sensitivity 82% and specificity 73%).

CONCLUSIONS

Cutoff values are considered a prerequisite for further investigating the clinical usefulness of measurements of IFX in patients maintained with IFX treatment.

摘要

背景/目的:英夫利昔单抗(IFX)在炎症性肠病(IBD)患者中,随着时间的推移,初始应答者的治疗效果往往会丧失。血清 IFX 谷浓度(TL)低与临床应答不良和结局不佳有关。维持最佳治疗性 IFX 浓度对于维持应答和获得良好的临床结局很重要。检测血清 IFX TL 有助于确定进一步的适当治疗方案。然而,儿童 IBD 中合适的治疗性 IFX TL 尚不确定。我们旨在确定与 IFX 维持治疗的实验室应答相关的 IFX TL 截断值。

方法

回顾性调查了 2008 年 12 月至 2015 年 3 月在三星医疗中心接受 IFX 输注的患有儿童 IBD 的患者。我们分析了来自 103 名儿科患者的 239 份血样。我们通过液相传感免疫测定法在诱导(6 周和 14 周)和维持治疗期间(>22 周,间隔 8 周)测量 IFX TL。

结果

在维持治疗期间,红细胞沉降率(ESR)与 IFX TL 之间存在显著相关性(相关系数,-0.11;p=0.0005)。使用 ESR 18mm/hr 的截断值来定义较高水平。接受者操作特征分析确定了最佳截断值:IFX TL>1.58µg/mL(敏感性 82%,特异性 73%)。

结论

截断值被认为是进一步研究 IFX 测量在接受 IFX 治疗的患者中的临床有用性的前提。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d234/6743797/cecc12f93416/gnl-13-541f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d234/6743797/a4daaed86332/gnl-13-541f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d234/6743797/c8f46e63c98c/gnl-13-541f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d234/6743797/cecc12f93416/gnl-13-541f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d234/6743797/a4daaed86332/gnl-13-541f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d234/6743797/c8f46e63c98c/gnl-13-541f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d234/6743797/cecc12f93416/gnl-13-541f3.jpg

相似文献

1
Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease.血清英夫利昔单抗清除率水平值可维持儿科炎症性肠病患者血液学缓解。
Gut Liver. 2019 Sep 15;13(5):541-548. doi: 10.5009/gnl18129.
2
Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.在接受英夫利昔单抗维持治疗的炎症性肠病患者中,英夫利昔单抗谷浓度随时间推移而下降。
Eur J Gastroenterol Hepatol. 2019 Feb;31(2):187-191. doi: 10.1097/MEG.0000000000001332.
3
The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.英夫利昔单抗谷浓度与儿童炎症性肠病疾病活动度的相关性
Scand J Gastroenterol. 2015;50(9):1110-7. doi: 10.3109/00365521.2015.1027264. Epub 2015 Apr 11.
4
Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease.英夫利昔单抗谷浓度及抗英夫利昔单抗抗体在儿童炎症性肠病患者中的临床应用
J Pediatr Gastroenterol Nutr. 2017 Feb;64(2):272-278. doi: 10.1097/MPG.0000000000001258.
5
Subcutaneous versus intravenous infliximab therapy - a real-world study: toward higher drug concentrations.皮下注射与静脉输注英夫利昔单抗治疗的真实世界研究:追求更高的药物浓度。
Eur J Gastroenterol Hepatol. 2024 Nov 1;36(11):1314-1318. doi: 10.1097/MEG.0000000000002835. Epub 2024 Aug 19.
6
Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease.优化英夫利昔单抗暴露预测的小儿炎症性肠病人群药代动力学模型。
Inflamm Bowel Dis. 2020 Feb 11;26(3):429-439. doi: 10.1093/ibd/izz143.
7
Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases.英夫利昔单抗药物和抗体水平与儿科炎症性肠病治疗结果的关系。
J Pediatr Gastroenterol Nutr. 2018 Oct;67(4):507-512. doi: 10.1097/MPG.0000000000002051.
8
Causes of Treatment Failure in Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study.英夫利昔单抗治疗炎症性肠病儿童治疗失败的原因:一项药代动力学研究。
J Pediatr Gastroenterol Nutr. 2019 Jan;68(1):37-44. doi: 10.1097/MPG.0000000000002112.
9
Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease.诱导期英夫利昔单抗充分暴露可预测儿童炎症性肠病患者的缓解情况。
J Pediatr Gastroenterol Nutr. 2019 Jun;68(6):847-853. doi: 10.1097/MPG.0000000000002265.
10
New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases.炎症性肠病患者英夫利昔单抗治疗药物监测的新步骤。
Br J Clin Pharmacol. 2019 Apr;85(4):722-728. doi: 10.1111/bcp.13845. Epub 2019 Jan 28.

引用本文的文献

1
Clinical and Biochemical Factors Associated with Infliximab Pharmacokinetics in Paediatric Patients with Inflammatory Bowel Disease.炎症性肠病患儿英夫利昔单抗药代动力学相关的临床和生化因素
J Clin Med. 2025 Jan 27;14(3):845. doi: 10.3390/jcm14030845.
2
Infliximab adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn's disease.英夫利昔单抗、阿达木单抗:在选择抗肿瘤坏死因子药物治疗儿童克罗恩病时需要考虑的要点。
World J Gastroenterol. 2023 May 14;29(18):2784-2797. doi: 10.3748/wjg.v29.i18.2784.
3
Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom?

本文引用的文献

1
Evaluation of Infliximab Therapy in Children with Crohn's Disease Using Trough Levels Predictors.使用谷浓度预测指标评估英夫利昔单抗治疗克罗恩病患儿的疗效
Dig Dis. 2018;36(1):40-48. doi: 10.1159/000477962. Epub 2017 Aug 18.
2
Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice.抗TNF单克隆抗体在炎症性肠病中的药代动力学:为当前治疗增添价值。
J Clin Pharmacol. 2015 Mar;55 Suppl 3:S39-50. doi: 10.1002/jcph.374.
3
Optimizing the use of biological therapy in patients with inflammatory bowel disease.
炎症性肠病患者生物制剂的治疗药物监测:如何、何时以及针对谁?
Gut Liver. 2022 Jul 15;16(4):515-524. doi: 10.5009/gnl210262. Epub 2021 Oct 21.
4
Advances in Therapeutic Drug Monitoring in Biologic Therapies for Pediatric Inflammatory Bowel Disease.儿童炎症性肠病生物治疗中治疗药物监测的进展
Front Pediatr. 2021 May 26;9:661536. doi: 10.3389/fped.2021.661536. eCollection 2021.
5
Albumin-to-Globulin Ratio at 1 Year after Anti-Tumor Necrosis Factor α Therapy Can Serve as a Prognostic Biomarker in Pediatric Crohn's Disease Patients.肿瘤坏死因子 α 治疗 1 年后的白蛋白-球蛋白比值可作为儿童克罗恩病患者的预后生物标志物。
Gut Liver. 2022 Jan 15;16(1):71-80. doi: 10.5009/gnl20322.
6
Therapeutic Drug Monitoring and Outcome of Infliximab Therapy in Pediatric Onset Inflammatory Bowel Disease.儿童期起病的炎症性肠病中英夫利昔单抗治疗的治疗药物监测及疗效
Front Pediatr. 2021 Jan 13;8:623689. doi: 10.3389/fped.2020.623689. eCollection 2020.
7
Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology.生物制剂治疗患者的治疗药物监测:来自胃肠病学的经验教训。
Curr Opin Rheumatol. 2020 Jul;32(4):371-379. doi: 10.1097/BOR.0000000000000713.
优化炎症性肠病患者的生物治疗。
Gastroenterol Rep (Oxf). 2015 Feb;3(1):63-8. doi: 10.1093/gastro/gou087. Epub 2015 Jan 6.
4
Infliximab "Top-Down" Strategy is Superior to "Step-Up" in Maintaining Long-Term Remission in the Treatment of Pediatric Crohn Disease.英夫利昔单抗“自上而下”策略在维持儿童克罗恩病长期缓解治疗方面优于“逐步升级”策略。
J Pediatr Gastroenterol Nutr. 2015 Jun;60(6):737-43. doi: 10.1097/MPG.0000000000000711.
5
Infliximab therapy in pediatric patients 7 years of age and younger.英夫利昔单抗在7岁及以下儿科患者中的治疗应用。
J Pediatr Gastroenterol Nutr. 2014 Dec;59(6):758-62. doi: 10.1097/MPG.0000000000000533.
6
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease.欧洲克罗恩病和结肠炎组织/欧洲儿科胃肠病、肝病和营养学会关于儿童克罗恩病药物治疗的共识指南。
J Crohns Colitis. 2014 Oct;8(10):1179-207. doi: 10.1016/j.crohns.2014.04.005. Epub 2014 Jun 6.
7
Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.英夫利昔单抗联合硫唑嘌呤治疗溃疡性结肠炎优于两药单药治疗。
Gastroenterology. 2014 Feb;146(2):392-400.e3. doi: 10.1053/j.gastro.2013.10.052.
8
Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.在对 TNF 治疗应答丧失的克罗恩病患者中,个体化治疗比剂量强化更具成本效益:一项随机对照试验。
Gut. 2014 Jun;63(6):919-27. doi: 10.1136/gutjnl-2013-305279. Epub 2013 Jul 22.
9
Optimizing anti-TNF treatments in inflammatory bowel disease.优化炎症性肠病的抗 TNF 治疗。
Autoimmun Rev. 2014 Jan;13(1):24-30. doi: 10.1016/j.autrev.2013.06.002. Epub 2013 Jun 19.
10
Antibody response to infliximab and its impact on pharmacokinetics can be transient.英夫利昔单抗的抗体应答及其对药代动力学的影响可能是短暂的。
Am J Gastroenterol. 2013 Jun;108(6):962-71. doi: 10.1038/ajg.2013.12. Epub 2013 Feb 19.